Research>>Clinical Trials>>Women with SWCAH Sought for Study

Women with SWCAH Sought for Study

People with CAH make too many male hormones (androgens). This causes male characteristics to appear early or inappropriately.  The purpose of this study is to determine the best dose of abiraterone acetate needed to decrease androgen levels in adult women with congenital adrenal hyperplasia (CAH).  The study will be conducted in Dallas, Texas and Ann Arbor, Michigan.

Abiraterone acetate has been approved by the Food and Drug Administration (FDA) for use in men with metastatic prostate cancer and is currently sold as Zytiga. It is also being studied in several other illnesses including CAH.

Abiraterone acetate is not FDA approved for the treatment of CAH.  The best dose identified in this study will be used to determine the starting dose in a subsequent study.

Eligibility criteria:

• Age Range: From 18 To 999 years
• Gender:Female
• Ethnicity: All
• Race: All
• Smoking: Both Smoking and No-Smoking
• This study is seeking: Patient with Specific Condition
• 21-hydroxylase deficiency
• ALL of the following must be met for inclusion:
• Adult woman (18 and older)
• Diagnosed with classic congential adrenal hyperlplasia
• Pre-menopausal

Interested in participating?
https://www.umms.med.umich.edu/umclinicalstudies/detail_pub_study.do?
show=YES&id=8265&TYPE=
734-615-8914  or  cmcr@med.umich.edu